Literature DB >> 23089753

Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis.

Carlo Tascini1, Antonello Di Paolo, Roberta Poletti, Sarah Flammini, Michele Emdin, Ilaria Ciullo, Enrico Tagliaferri, Annette Moter, Francesco Menichetti.   

Abstract

In a patient with mitral-aortic native-valve Streptococcus oralis endocarditis, daptomycin concentrations in aortic and mitral valves were 8.6 and 30.8 μg/g, respectively, and 26 μg/g in the mitral vegetation. In the case of porcine-aortic-valve Staphylococcus epidermidis endocarditis, the daptomycin concentrations were 53.1 μg/g in the valve and 18.1 μg/g in perivalvular tissues. Daptomycin achieved apparently adequate tissue concentrations. S. epidermidis was eradicated, whereas Streptococcus oralis persisted, and its daptomycin MIC displayed a 4-fold increase.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089753      PMCID: PMC3535905          DOI: 10.1128/AAC.01608-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.

Authors:  Jennifer M Streit; Judith N Steenbergen; Grace M Thorne; Jeffrey Alder; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2005-02-18       Impact factor: 5.790

3.  A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma.

Authors:  Marialuisa Polillo; Carlo Tascini; Marianna Lastella; Paolo Malacarne; Laura Ciofi; Bruno Viaggi; Guido Bocci; Francesco Menichetti; Romano Danesi; Mario Del Tacca; Antonello Di Paolo
Journal:  Ther Drug Monit       Date:  2010-04       Impact factor: 3.681

4.  Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.

Authors:  C García-de-la-Mària; F Marco; Y Armero; D Soy; A Moreno; A del Río; M Almela; C Cervera; S Ninot; C Falces; C A Mestres; J M Gatell; M T Jiménez de Anta; J M Miró
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

5.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

6.  Molecular methods for diagnosis of infective endocarditis.

Authors:  Annette Moter; Michele Musci; Dinah Schmiedel
Journal:  Curr Infect Dis Rep       Date:  2010-07       Impact factor: 3.725

7.  Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.

Authors:  F Caron; M D Kitzis; L Gutmann; A C Cremieux; B Maziere; J M Vallois; A Saleh-Mghir; J F Lemeland; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Fluorescence in situ hybridization to improve the diagnosis of endocarditis: a pilot study.

Authors:  C Mallmann; S Siemoneit; D Schmiedel; A Petrich; D M Gescher; E Halle; M Musci; R Hetzer; U B Göbel; A Moter
Journal:  Clin Microbiol Infect       Date:  2009-08-20       Impact factor: 8.067

9.  In vivo pharmacodynamic activity of daptomycin.

Authors:  Nasia Safdar; David Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  9 in total
  6 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

Review 2.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.

Authors:  Jose M Munita; Barbara E Murray; Cesar A Arias
Journal:  Int J Antimicrob Agents       Date:  2014-09-02       Impact factor: 5.283

Review 3.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

4.  Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.

Authors:  Cristina García-de-la-Mària; Juan M Pericas; Ana Del Río; Ximena Castañeda; Xavier Vila-Farrés; Yolanda Armero; Paula A Espinal; Carlos Cervera; Dolors Soy; Carlos Falces; Salvador Ninot; Manel Almela; Carlos A Mestres; Jose M Gatell; Jordi Vila; Asuncion Moreno; Francesc Marco; Jose M Miró
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

5.  Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases.

Authors:  Daniela M Palma; Simone Giuliano; Andrea N Cracchiolo; Marco Falcone; Giancarlo Ceccarelli; Romano Tetamo; Mario Venditti
Journal:  Infection       Date:  2015-09-03       Impact factor: 3.553

Review 6.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.